Surprise! Bitcoin is getting no love from two of the world’s wealthiest men.
“I would short if there was an easy way to do it,” Bill Gates said Monday in an interview on CNBC. Gates said he had previously received some Bitcoin as a birthday present, but sold those a few years later. “As an asset class, you’re not producing anything.”
Fellow billionaire and Gates pal Warren Buffett said the largest cryptocurrency is "probably rat poison squared" at Berkshire Hathaway Inc.’s annual shareholder meeting on Saturday.
#lazy-img-327501204:before{padding-top:56.25%;}
The comments may be weighing on Bitcoin’s price as the digital asset slumps 4.2 percent at 9:30 a.m. New York time to $9,273, its first decline in four business days. Bitcoin climbed as much as 50 percent since slumping near $6,500 four weeks ago, but the rally has lost steam before crossing $10,000.
Top Warren Buffett Stocks To Invest In 2019: MannKind Corporation(MNKD)
Advisors’ Opinion:
- [By Brian Feroldi]
MannKind (NASDAQ:MNKD) was founded in 2001 with a simple mission: to make treating chronic and acute diseases easier. The company’s big idea was to develop technology that enabled drugs to be inhaled through the lungs instead of needing to be injected through the skin.
- [By George Budwell]
MannKind Corporation (NASDAQ:MNKD) reported its second-quarter earnings yesterday, and the numbers didn’t paint a pretty picture, to put it lightly. In fact, the struggling inhaled insulin company is facing a serious cash crisis that it might not be able to solve without drastic measures. Unfortunately for shareholders, one of those measures could be declaring bankruptcy.
- [By Motley Fool Staff]
MannKind Corporation’s (NASDAQ:MNKD) decision to develop an inhalable formulation of Remodulin has proved to be a savvy move. This week, Remodulin’s drug manufacturer, United Therapeutics (NASDAQ:UTHR), agreed to license MannKind’s early-stage version for $45 million, plus milestones and royalties. United Therapeutics’ cash provides the cash-strapped developer of Afrezza, an inhalable insulin, with much-needed financial flexibility, but MannKind still has a problem on its hands. Is this company’s stock worth buying?
- [By Money Morning Staff Reports]
However, it’s unlikely Netlist repeats these returns anytime soon. After looking at last week’s top performing penny stocks, we’ll show you a penny stock on the verge of jumping over 230%…
Penny Stock Current Share Price Last Week’s Gain
Netlist Inc. (Nasdaq: NLST) $0.83 542.67%
Mannkind Corp. (Nasdaq: MNKD) $1.80 79.09%
Fred’s Inc. (Nasdaq: FRED) $2.49 73.68%
Delcath Systems Inc. (OTCMKTS: DCTH) $3.70 72.63%
Gemphire Therapeutics Inc. (Nasdaq: GEMP) $1.96 50.71%
Bellerophon Therapeutics Inc. (Nasdaq: BLPH) $1.05 47.98%
Cel-Sci Corp. (NYSE: CVM) $3.78 44.78%
ParkerVision Inc. (OTCMKTS: PRKR) $0.60 29.42%
Superior Drilling Products Inc. (NYSE: SDPI) $2.63 29.23%
LiqTech International Inc. (NYSE: LIQT) $1.50 25.20%How to Profit off This $11.1 Billion Money Pool: By following a few simple steps, one IRS directive could help set you up to receive checks of up to $1,795 every single month thanks to a genius investment. Learn more…
- [By Paul Ausick]
Mannkind Corp. (NASDAQ: MNKD) traded down about 34% Friday to set a new 52-week low of $0.99. Shares closed at $1.50 on Thursday, and the 52-week high is $6.96. Volume was about five times the daily average of around 2 million. The struggling biopharma firm reported weak earnings last night.
Top Warren Buffett Stocks To Invest In 2019: ICON plc(ICLR)
Advisors’ Opinion:
- [By Max Byerly]
Get a free copy of the Zacks research report on Icon (ICLR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Stephan Byrd]
Icon Plc (NASDAQ:ICLR) hit a new 52-week high on Monday . The stock traded as high as $150.06 and last traded at $149.02, with a volume of 170901 shares. The stock had previously closed at $147.56.
- [By Stephan Byrd]
Financial Gravity Wealth Inc. acquired a new position in shares of Icon Plc (NASDAQ:ICLR) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,524 shares of the medical research company’s stock, valued at approximately $179,000.
Top Warren Buffett Stocks To Invest In 2019: Principal Financial Group Inc(PFG)
Advisors’ Opinion:
- [By Logan Wallace]
Get a free copy of the Zacks research report on Principal Financial Group (PFG)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Joseph Griffin]
KBC Group NV lowered its position in shares of Principal Financial Group Inc (NYSE:PFG) by 41.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 201,808 shares of the financial services provider’s stock after selling 142,313 shares during the period. KBC Group NV’s holdings in Principal Financial Group were worth $12,292,000 as of its most recent filing with the SEC.
- [By WWW.GURUFOCUS.COM]
For the details of Stilwell Value LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Stilwell+Value+LLC
These are the top 5 holdings of Stilwell Value LLCOFG Bancorp (OFG) – 1,614,868 shares, 14.1% of the total portfolio. Kingsway Financial Services Inc (KFS) – 3,780,889 shares, 12.63% of the total portfolio. HopFed Bancorp Inc (HFBC) – 627,128 shares, 7.62% of the total portfolio. Alcentra Capital Corp (ABDC) – 1,251,324 shares, 7.27% of the total portfolio. Shares added by 20.66%Sound Financial Bancorp Inc (SFBC) – 228,600 shares, 7.02% of th
Top Warren Buffett Stocks To Invest In 2019: Array BioPharma Inc.(ARRY)
Advisors’ Opinion:
- [By Keith Speights]
Three biotechs that have reached this critical milestone with their respective new drugs and await key FDA approval decisions in June are Array BioPharma (NASDAQ:ARRY), GW Pharmaceuticals (NASDAQ:GWPH), and Incyte (NASDAQ:INCY). Here’s what the FDA’s upcoming decisions mean for each of these biotechs.
- [By Stephan Byrd]
Array Biopharma Inc (NASDAQ:ARRY) traded down 7.2% on Friday . The company traded as low as $13.48 and last traded at $13.98. 4,906,836 shares changed hands during trading, an increase of 68% from the average session volume of 2,921,348 shares. The stock had previously closed at $15.06.
- [By Cory Renauer]
It looks like the benefit-to-risk ratio is off the charts for larotrectinib as well as LOXO-292, but the number of patients with TRK fusion cancers that fail multiple existing treatments is somewhere between 1,500 and 5,000 each year in the U.S. Investors also need to understand that Loxo Oncology licensed its candidates from Array Biopharma (NASDAQ:ARRY) and owes its partner substantial milestone payments and mid-single-digit royalties on any sales they might generate. Loxo has partnered with Bayer AG (NASDAQOTH:BAYRY), and if approved, the German giant will share U.S. profits with Loxo and pay double-digit royalties on sales abroad.
Top Warren Buffett Stocks To Invest In 2019: Sapiens International Corporation N.V.(SPNS)
Advisors’ Opinion:
- [By Shane Hupp]
Sapiens International (NASDAQ:SPNS) issued its quarterly earnings results on Monday. The technology company reported $0.13 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.10 by $0.03, Briefing.com reports. Sapiens International had a net margin of 0.13% and a return on equity of 6.81%. The business had revenue of $71.09 million for the quarter, compared to analyst estimates of $67.68 million. During the same quarter in the prior year, the business posted $0.02 EPS. Sapiens International’s revenue for the quarter was up 25.8% compared to the same quarter last year.
- [By Logan Wallace]
Sapiens International (NASDAQ: SPNS) and NetSol Technologies (NASDAQ:NTWK) are both small-cap computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on Sapiens International (SPNS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com